William Gerber, MD was an Investment Partner with Bay City Capital from 2004 to 2013. He retired from his role as Investment Partner; however, he retains board positions with certain prior investments. Previous to his role with Bay City Capital, he was President and Chief Executive Officer of Epoch BioSciences, which was acquired by Nanogen in 2004. Prior to Epoch, Dr. Gerber served as President and Chief Executive Officer of diaDexus LLC, a joint venture established by Incyte Pharmaceuticals and SmithKline Beecham to apply genomics to the discovery of novel diagnostic products. Dr. Gerber also served as Vice President and Chief Operating Officer of Onyx Pharmaceuticals, as President of Chiron Diagnostics, and as Senior Vice President and General Manager of the PCR Division of Cetus Corporation. He also served on and was President of the Board of Medical Quality Assurance, State of California.
Dr. Gerber is a member of the board of directors of Omicia and SynGen, Inc.. He received his MD and BS degrees from University of California, San Francisco Medical Center after attending Dartmouth College.